ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

NCT ID: NCT02009579

Last Updated: 2024-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2023-10-31

Brief Summary

Indication:

Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed.

Study design:

This is a phase II randomized, double blind and placebo controlled trial evaluating the efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel followed by Nintedanib/placebo maintenance in the treatment of patients with advanced or recurrent cervical cancer.

A total of 120 patients will be randomized between the experimental and control arm in a 1:1 ratio. Randomization will be stratified for 1previous chemotherapy for metastatic disease (yes/no) and 2disease status (Stage IVB primary versus recurrent disease).

Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.

Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.

Subjects without evidence of disease progression after completion or discontinuation of the study treatment will be followed until radiographic disease progression, withdrawal of consent or death.

Conditions

Uterine Cervical Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Experimental arm

Nintedanib/vargatef

Group Type: ACTIVE_COMPARATOR

Nintedanib

Intervention Type: DRUG

Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.

Comparator arm

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.

Interventions

Nintedanib

Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.

Intervention Type: DRUG

Placebo

Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.

Intervention Type: DRUG

Other Intervention Names

Vargatef

Eligibility Criteria

Inclusion Criteria

• Female subjects more than 18 years of age
• Histologically or cytologically confirmed advanced ([FIGO] stage IVB), or recurrent/persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix will be eligible.
• Prior treatment with angiogenesis inhibitors is allowed
• Up to one prior line of chemotherapy for metastatic cervical cancer is allowed.

• Treatment of primary disease with concomitant cisplatinum chemotherapy during radiotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
• Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery is allowed and does not count as a line of chemotherapy for metastatic disease.
• Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery followed by adjuvant radiochemotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
• Treatment of primary disease with neoadjuvant chemotherapy before radical local surgery followed by adjuvant radiotherapy is allowed and does not count as a line of chemotherapy for metastatic disease.
• Life expectancy at least 3 months.
• ECOG Performance status score of 0 or 1
• At least one measurable lesion according to RECIST 1.1 criteria
• Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation

Exclusion Criteria

• Known hypersensitivity to the trial drugs or to their excipients (including peanut or soya).
• Brain or leptomeningeal metastases.
• Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels.
• Tumor infiltrating the mucosa of the bowel or bladder, or known fistulas between the tumor and the gastrointestinal or urinary tract.
• Radiographic evidence of cavitary or necrotic tumours
• Treatment with other investigational drugs or treatment in another clinical trial within the past 4 weeks before start of therapy or concomitantly with the trial.
• Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid <325 mg per day).
• Major injuries within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period.
• History of clinically significant haemorrhagic or thromboembolic event in the past 6 months.
• Known inherited predisposition to bleeding or thrombosis.
• Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina within the past 6 months, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion).
• History of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months.
• Abnormal renal, liver or bone marrow function defined as:

• Proteinuria CTCAE grade 2 or greater
• Creatinin > 2 ULN or GFR < 30 ml/min
• Hepatic function: total bilirubin outside of normal limits; ALT or AST > 1.5 ULN in pts without liver metastasis. For Pts with liver metastases: total bilirubin outside of normal limits, ALT or AST > 2.5 ULN
• Coagulation parameters: International normalised ratio (INR) > 2, prothrombin time (PT) and partial thromboplastin time (PTT) > 50% of deviation of institutional ULN
• Absolute neutrophil count ( ANC) < 1500/µl, platelets < 100000/µl, haemoglobin < 9.0 g/dl
• Other malignancies within the past 3 years or other malignancy with recurrence in the past 3 years or with high risk of recurrence in the first year. In exception to this rule, the following malignancies may be included: non-melanomatous skin cancer (if adequately treated) , any premalignant (e.g. in situ) carcinoma, or basocellular carcinoma.
• Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
• Active or chronic hepatitis C and/or B infection or known HIV infection (based on medical file, only for Italy a mandatory screening test for HIV should be performed for all patients who did not have this test within the last 3 months before the study treatment start).
• Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.
• Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study.
• Patients of child-bearing potential who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner or sexual abstinence for participating females) during the trial and for at least three months after end of active therapy.
• Pregnancy or breast feeding, female patients must have a negative pregnancy test (β-HCG test in urine or serum) prior to commencing study treatment, if applicable.
• Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
• Active alcohol or drug abuse.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Grupo Español de Investigación en Cáncer de Ovario

OTHER

Sponsor Role: collaborator

Mario Negri Gynecologic Oncology group (MaNGO)

OTHER

Sponsor Role: collaborator

Multicenter Italian Trials in Ovarian Cancer (MITO)

UNKNOWN

Sponsor Role: collaborator

North Eastern German Society of Gynaecological Oncology

OTHER

Sponsor Role: collaborator

Belgian Gynaecological Oncology Group

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU Saint-Pierre

Brussels, , Belgium

Institut Jules Bordet

Brussels, , Belgium

Grand Hopital de Charleroi

Charleroi, , Belgium

UZ Antwerpen

Edegem, , Belgium

AZ Groeninge

Kortrijk, , Belgium

UZ Leuven

Leuven, , Belgium

CHU de Liège

Liège, , Belgium

CHR Citadelle

Liège, , Belgium

Clinique et maternite St. Elisabeth

Namur, , Belgium

Cliniques Universitaires mont godinne

Yvoir, , Belgium

Charité Med Uni Berlin

Berlin, , Germany

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, , Germany

Kliniken Essen Mitte

Essen, , Germany

Georg-August University Göttingen

Göttingen, , Germany

Medical University Greifswald

Greifswald, , Germany

University Tübingen

Tübingen, , Germany

Centro Riferimento Oncologico

Aviano, , Italy

Spedali Civili

Brescia, , Italy

Azienda Ospedaliera Cannizzaro

Catania, , Italy

National Cancer Institute

Milan, , Italy

Istituto Nazionale Tumori-Pascale Naples

Naples, , Italy

Padova Istituti Oncologico Veneto

Padua, , Italy

University Pisa

Pisa, , Italy

AUSL Reggio Emilia

Reggio Emilia, , Italy

Poloclinico A Gemelli

Rome, , Italy

Mauriziano -Torino

Torino, , Italy

S. Anna Torino

Torino, , Italy

Hospital Provincial Reina Sofia

Córdoba, , Spain

H. Ramón y Cajal

Madrid, , Spain

Hospital Clinico San Carlos

Madrid, , Spain

Hospital Universitario Morales Meseguer

Murcia, , Spain

Hospital Son Llatzer

Palma Mallorca, , Spain

Countries

Belgium; Germany; Italy; Spain

Related Links

http://www.bgog.eu/

BGOG website

http://www.esgo.org/engot/Pages/AboutENGOT.aspx

ENGOT website

Other Identifiers

BGOG-cx1/ENGOT-cx1

Identifier Type: -

Identifier Source: org_study_id